Cannabinoid & Endocannabinoid Drug Development Summit

The Cannabinoid & Endocannabinoid Drug Development Summit focuses on cannabinoid and endocannabinoid drug development, exploring preclinical research, CB1-targeted therapies, clinical trial optimization, regulatory frameworks, and expanding therapeutic applications in metabolic and related diseases.

Key Topics

• Preclinical considerations to enhance cannabinoid deliverabilty & sustainabilty
• The potential of CB1-targeting therapies for obesity & diabetes treatment options
• Regulatory landscape: policies, oversight, GMP & safety for cannabinoid research
• CB1: from preclinical insights to therapeutic breakthroughs
• Cannabinoid & ECS-targeting drug development: decoding the unique considerations & utilizing innovative technologies
• Uniting forces in cannabinoid drug development & expanding therapeutic targets
• Research priorities in cannabinoid & ECS-targeting drug development
• Progressing cannabinoid clinical research & optimizing trial design